Avadel Pharmaceuticals PLC (AVDL NASDAQ) stock market data APIs
$8.7654
0.57(6.5%)
as of June 30, 2025
Try our APIs with
free plan!
Avadel Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Prev. Close
8.7654
Open
9.3324
High
9.4909
Low
8.6981
52 wk Range
6.38-17.298
Market Cap
891 M
Shares Outstanding
96 900 K
Revenue
194 M
EPS
-0.05
Beta
1.632
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avadel Pharmaceuticals PLC data using free add-ons & libraries
Get Avadel Pharmaceuticals PLC Fundamental Data
Avadel Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 194 M
- EBITDA: -16 400 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avadel Pharmaceuticals PLC News
New
Avadel stock rises after appeals court upholds LUMRYZ approval
Investing.com -- Avadel Pharmaceuticals PLC (NASDAQ:AVDL) stock rose 4.7% after a U.S. appeals court unanimously upheld the FDA’s approval of LUMRYZ, the company’s once-at-bedtime treatment for na...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June...
Avadel Pharmaceuticals faces board challenge from investor ASL Strategic Value - report
Investing.com -- Investor ASL Strategic Value Fund plans to urge shareholders to vote against Avadel Pharmaceuticals’ (NASDAQ:AVDL) entire board of directors, according to the The Wall Street Journa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
